問卷

TPIDB > 臨床試驗主持人

臨床試驗主持人



更新時間:2023-09-19

黃毓惠Huang, Yu-Huei
  • 計畫主持人
  • 執行臨床試驗年資 17 年 9 個月
  • huangyh@adm.cgmh.org.tw

臨床試驗成就

Responsible for conducting of clinical trials and strictly adhere to the study protocol requirements by following Good Clinical Practice(GCP). Have conducted over 30 clinical trials, inculding Phase I-IV, as a principal investigator and cooperate with AbbVie, Eli-Lilly, Novartis Pharmaceuticals Corporation, Pfizer, Sanofi, Galderma and Janssen Pharmaceutica.

* Key Qualifications and clinical trial related:
1.United BioPharma, Inc. (UBP) Clinical Trial Steering Committee member
2.Phase III global trial top 1 recruiting site in Asia - Mirikizumab in Moderate to Severe Psoriasis Patients (Eli Lilly and Company)
3.TFDA inspection experiences:
(1) Guselkumab (Janssen-Cilag International N.V.) active psoriatic arthritis including those previously treated with Anti-TNFα Agents
(2) Ixekizumab (Eli Lilly and Company) - modifying antirheumatic experienced patient with active psoriatic arthritis
(3) Botulax inj.R - evaluate the safety and efficacy of Botulax treatment of glabellar frown lines
4.Conducted in clinical trials in which FDA IND application approved:
(1) Secukinumab、(2) Guselkumab、(3) Ixekizumab、(4) Baricitinib、(5) Upadacitinib、(6) Risankizumab、(7) Tofacitinib

研究領域

  • 乾癬,異位性皮膚炎,流行病學研究,皮膚病學,整形美容手術,皮膚腫瘤外科

專業經歷

台北長庚醫院

Attending Physician

Dermatology

2003- 迄今

長庚大學

副教授

醫學系皮膚科

學歷

台灣大學

醫學系

MD

1992-1999

台灣大學

流行病學與預防醫學研究所

碩士

2009-2011

臨床試驗案

全部案件89

2016

總案件數 89

  • I 0

  • I/II 0

  • II 16

  • II/III 1

  • III 67

  • IV 1

  • 其他 4

依試驗規模分類

5件

台灣多中心案件

台灣單中心案件

0

台灣多中心案件

5

多國多中心案件

84